ArticleBiomaterials2020
A nephrotoxicity-free, iron-based contrast agent for magnetic resonance imaging of tumors.
Abstract read
In one paragraph
Article in Biomaterials, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Metal-free nitroxide radical-based theranostic agent for MRI-guided therapy of ulcerative colitis.Materials today. Bio · 2026Article
- Nanomedicine in Organ Transplantation: From Graft Preservation and Repair to Immunomodulation and Monitoring.Theranostics · 2026Review
- Ferrocene-Functionalized Black Phosphorus Nanoplatform Enables Targeted and Prolonged MRI Visualization of Atherosclerotic Plaques.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Novel non‑metal‑based contrast agents for MR imaging: Emerging approaches and clinical perspectives (Review).International journal of oncology · 2025Review
- Potential Applications of Rare Earth Metal Nanoparticles in Biomedicine.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Iron(III)-Quercetin Complex: In Vivo Acute Toxicity and Biodistribution of Novel MRI Agent.International journal of nanomedicine · 2025Article
- Highly Efficient Synergistic Chemotherapy and Magnetic Resonance Imaging for Targeted Ovarian Cancer Therapy Using Hyaluronic Acid-Coated Coordination Polymer Nanoparticles.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- A Gold Nanocage Probe Targeting Survivin for the Diagnosis of Pancreatic Cancer.Pharmaceutics · 2023Article
- Article
- Stimuli-responsive crosslinked nanomedicine for cancer treatment.Exploration (Beijing, China) · 2022Review
- Facile Synthesis of Weakly Ferromagnetic Organogadolinium Macrochelates-Based TAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- Biodegradable and biocompatible exceedingly small magnetic iron oxide nanoparticles for TJournal of nanobiotechnology · 2022Article
- Article
- Novel monodisperse FePt nanocomposites for T2-weighted magnetic resonance imaging: biomedical theranostics applications.Nanoscale advances · 2022Review
- Iron-crosslinked Rososome with robust stability and high drug loading for synergistic cancer therapy.Journal of controlled release : official journal of the Controlled Release Society · 2021Article
- Telodendrimers: Promising Architectural Polymers for Drug Delivery.Molecules (Basel, Switzerland) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Xiangdong XueDepartment of Biochemistry and Molecular Medicine, UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, CA, 95817, USA.
Ruonan BoDepartment of Biochemistry and Molecular Medicine, UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, CA, 95817, USA; School of Veterinary Medicine, Yangzhou University, Yangzhou, 225009, PR China.
Haijing QuDepartment of Biochemistry and Molecular Medicine, UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, CA, 95817, USA.
Bei JiaDepartment of Biochemistry and Molecular Medicine, UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, CA, 95817, USA.
Wenwu XiaoDepartment of Biochemistry and Molecular Medicine, UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, CA, 95817, USA.
Ye YuanDepartment of Biochemistry and Molecular Medicine, UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, CA, 95817, USA.
Natalia VapniarskyDepartment of Pathology, Microbiology, and Immunology, University of California, Davis, Davis, CA, 95616, USA.
Aaron LindstromDepartment of Biochemistry and Molecular Medicine, UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, CA, 95817, USA.
Hao WuDepartment of Biochemistry and Molecular Medicine, UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, CA, 95817, USA.
Dalin ZhangDepartment of Biochemistry and Molecular Medicine, UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, CA, 95817, USA.
Longmeng LiDepartment of Biochemistry and Molecular Medicine, UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, CA, 95817, USA.
Marina RicciDepartment of Biochemistry and Molecular Medicine, UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, CA, 95817, USA.
Zhao MaDepartment of Biochemistry and Molecular Medicine, UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, CA, 95817, USA.
Zheng ZhuDivision of Hematology and Oncology, Department of Internal Medicine, School of Medicine, University of California Davis, Sacramento, CA, 95817, USA.
Tzu-Yin LinDivision of Hematology and Oncology, Department of Internal Medicine, School of Medicine, University of California Davis, Sacramento, CA, 95817, USA.
Angelique Y LouieDepartment of Biomedical Engineering, University of California Davis, Davis, CA, 95616, USA.
Yuanpei LiDepartment of Biochemistry and Molecular Medicine, UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, CA, 95817, USA. Electronic address: lypli@ucdavis.edu.
Funding
Staff InvestigatorsP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI Laura Marcu · 2002 to 2026
$84.9MNano-Therapeutic Approaches for Oncogenic Herpesvirus-Mediated MalignanciesR01CA232845 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI IZUMIYA, YOSHIHIRO, LI, YUANPEI · 2018 to 2022
$3.2MTumor-penetrating nano-theranostics for image-guided interventions in spontaneous feline head and neck cancerR01DE029237 · NIDCR · UNIVERSITY OF CALIFORNIA AT DAVIS · PI LI, YUANPEI · 2020 to 2024
$2.9MStimuli-responsive crosslinked theranostics against advanced prostate cancerR01CA199668 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI LI, YUANPEI · 2015 to 2019
$1.8MSmart targeting nano-theranostics for image-guided drug delivery to pediatric brain tumorsR01HD086195 · NICHD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI LI, YUANPEI · 2016 to 2020
$1.6MNCI NIH HHS P30 CA093373NCI NIH HHS R01 CA199668NCI NIH HHS R01 CA232845NICHD NIH HHS R01 HD086195NIDCR NIH HHS R01 DE029237
Abstract
Gadolinium-based contrast agents (GBCAs) are the most widely used T
Indexed as
NeoplasmsRenal InsufficiencyAnimalsContrast MediaGadoliniumHumansIronMagnetic Resonance ImagingMiceContrast MediaGadoliniumIronContrast agentsMagnetic resonance imagingNanoparticleNephrotoxicity-freeTumor imaging
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.